Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 17/20 | 0.44 |
| ▸ | FNTB | P49356 | 17/20 | 0.44 |
| ▸ | PGGT1B | P53609 | 13/20 | 0.44 |
| ▸ | NPY4R | P50391 | 3/20 | 0.41 |
| ▸ | NPY1R | P25929 | 2/20 | 0.41 |
| ▸ | NPY2R | P49146 | 2/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29985357 | 1.00 | FNTA (0.44) | FNTAFNTBPGGT1BNPY4RNPY1R | |
| SCHEMBL29527234 | 0.91 | FNTA (0.51) | FNTAFNTBPGGT1BNPY4RNPY1R | |
| SCHEMBL29789057 | 0.89 | NPY4R (0.50) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30761725 | 0.89 | FNTA (0.49) | FNTAFNTBPGGT1BNPY4RNPY1R | |
| SCHEMBL31643025 | 0.88 | FNTA (0.49) | FNTAFNTBPGGT1B | |
| SCHEMBL30479333 | 0.88 | FNTA (0.51) | FNTAFNTBPGGT1BNPY4RNPY1R | |
| SCHEMBL30567411 | 0.87 | NPY4R (0.42) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31314418 | 0.87 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30117177 | 0.87 | PDCD1LG2 (0.42) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL9189133 | 0.87 | FNTA (0.54) | FNTAFNTBPGGT1BNPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | FNTA 445/4885FNTB 837/4885PGGT1B 2074/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | FNTA 445/4885FNTB 837/4885PGGT1B 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.